CareDx, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
CareDx, Inc. - overview
Established
1998
Location
Brisbane, CA, US
Primary Industry
Biotechnology
About
CareDx, Inc. is a biotechnology company specializing in transplant diagnostics, providing innovative noninvasive testing solutions to improve patient outcomes in organ transplantation. Founded in 1998 in Brisbane, US, CareDx, Inc. offers advanced solutions for the transplant sector, particularly for kidney, heart, and lung transplants.
The company has pivoted over the years to focus on noninvasive testing, such as AlloSure and AlloMap. Jay Graham is the founder, and the current executives include Anders Karlsson, D Wightman, Peter Maag, Reginald Seeto, and Terence Dphil. CareDx has raised a total of USD 22. 16 mn, with the latest funding round being a PIPE amounting to USD 22.
16 mn. CareDx specializes in providing noninvasive surveillance tests for transplant patients, such as AlloSure and AlloMap, which utilize advanced cell-free DNA (cfDNA) technology. These products enable healthcare professionals to monitor transplant health effectively. Additionally, CareDx offers comprehensive software and services to enhance operational processes within transplant centers, ensuring better patient management.
They serve over 150 transplant centers in North America and are working toward expanding their international market presence. In the most recent fiscal year 2024, CareDx reported a revenue of USD 333. 79 mn and an EBITDA of USD 60. 52 mn.
Their revenue model is based on direct sales of testing products and software services to healthcare providers and transplant centers, which reflects their advanced technological contributions to patient care. CareDx plans to launch new products designed to enhance monitoring in the transplant sector, with specific release dates to be announced. The company is targeting expansion into international markets to increase its reach and accessibility, with concrete plans to penetrate these regions by 2025. The recent PIPE funding round of USD 22.
16 mn will be utilized to support these initiatives, ensuring that CareDx can further enhance its product offerings and expand its market presence.
Current Investors
Burrill & Company, Kleiner Perkins, Sprout Group
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Molecular Science, Genetics & Gene Therapy, Diagnostic, Medical & Imaging Laboratories
Website
www.xdx.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
CareDx, Inc. - timeline of key events
CareDx, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.